Volume 101 Number 7
Published online 29 September 2009 (1033 - 1224)
---------------------------------------------------------------------
Why not take a multifaceted look at your cancer genome?
Agilent offers a single microarray platform for CGH, miRNA, gene expression,
and DNA methylation, giving you a more complete view of the disease.
So why not use a research platform capable of meeting the complexity of cancer itself,
with DNA microarrays from Agilent. Learn more at
http://links.ealert.nature.com/ctt?kn=108&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
---------------------------------------------------------------------
British Journal of Cancer publishes high quality original papers and
reviews that make a significant contribution to increasing
understanding of the causes of cancer and to improving the treatment
and survival of patients.
Visit the journal online at http://links.ealert.nature.com/ctt?kn=42&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0 to view the
latest research and access selected articles FREE of charge.
---------------------------------------------------------------------
British Journal of Cancer has an impact factor of 4.846*
2008 Journal Citation Reports (Thomson Reuters, 2009)
----------------------
CLINICAL STUDIES
----------------------
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
A Okines, O del Puerto, D Cunningham, I Chau, E Van Cutsem, L Saltz and J Cassidy
Abstract: http://links.ealert.nature.com/ctt?kn=4&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=86&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group
P Garcia-Alfonso, A Munoz-Martin, M Mendez-Urena, R Quiben-Pereira, E Gonzalez-Flores and G Perez-Manga
Abstract: http://links.ealert.nature.com/ctt?kn=85&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=84&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker
P N Munster, D Marchion, S Thomas, M Egorin, S Minton, G Springett, J-H Lee, G Simon, A Chiappori, D Sullivan and A Daud
Abstract: http://links.ealert.nature.com/ctt?kn=91&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=90&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study
J-F Rossi, J Moreaux, D Hose, G Requirand, M Rose, V Rouille, I Nestorov, G Mordenti, H Goldschmidt, A Ythier and B Klein
Abstract: http://links.ealert.nature.com/ctt?kn=89&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=88&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
C Kosmas, N Mylonakis, G Tsakonas, G Vorgias, N Karvounis, N Tsavaris, T Daladimos, N Kalinoglou, N Malamos, T Akrivos and A Karabelis
Abstract: http://links.ealert.nature.com/ctt?kn=119&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=121&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial
G Ferrandina, G Sallustio, A Fagotti, G Vizzielli, A Paglia, E Cucci, A Margariti, L Aquilani, G Garganese and G Scambia
Abstract: http://links.ealert.nature.com/ctt?kn=13&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=15&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom
H E Campbell, M A Taylor, A L Harris and A M Gray
Abstract: http://links.ealert.nature.com/ctt?kn=14&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=17&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Cause-specific mortality in classic Kaposi's sarcoma: a population-based study in Italy (1995-2002)
V Ascoli, G Minelli, M Kanieff, R Crialesi, L Frova and S Conti
Abstract: http://links.ealert.nature.com/ctt?kn=16&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=19&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Bladder cancer in cancer patients: population-based estimates from a large Swedish study
J Lorenzo Bermejo, J Sundquist and K Hemminki
Abstract: http://links.ealert.nature.com/ctt?kn=18&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=22&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
----------------------
TRANSLATIONAL THERAPEUTICS
----------------------
Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model
M Yashiro, O Shinto, K Nakamura, M Tendo, T Matsuoka, T Matsuzaki, R Kaizaki, M Ohira, A Miwa and K Hirakawa
Abstract: http://links.ealert.nature.com/ctt?kn=21&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=93&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma
N M A White, M Mathews, G M Yousef, A Prizada, C Popadiuk and J J E Dore
Abstract: http://links.ealert.nature.com/ctt?kn=106&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=107&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity
B J Stish, S Oh, H Chen, A Z Dudek, R A Kratzke and D A Vallera
Abstract: http://links.ealert.nature.com/ctt?kn=104&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=105&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
----------------------
MOLECULAR DIAGNOSTICS
----------------------
The actin-bundling protein fascin is overexpressed in colorectal adenomas and promotes motility in adenoma cells in vitro
D Qualtrough, K Singh, N Banu, C Paraskeva and M Pignatelli
Abstract: http://links.ealert.nature.com/ctt?kn=101&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=103&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells
D Dingli, F A C C Chalub, F C Santos, S Van Segbroeck and J M Pacheco
Abstract: http://links.ealert.nature.com/ctt?kn=99&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=100&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement
C S Foster, A R Dodson, L Ambroisine, G Fisher, H Moller, J Clark, G Attard, J De-Bono, P Scardino, V E Reuter, C S Cooper, D M Berney and J Cuzick on behalf of the Trans-Atlantic Prostate Group
Abstract: http://links.ealert.nature.com/ctt?kn=94&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=96&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility
T Nedjadi, N Kitteringham, F Campbell, R E Jenkins, B K Park, P Navarro, F Ashcroft, A Tepikin, J P Neoptolemos and E Costello
Abstract: http://links.ealert.nature.com/ctt?kn=122&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=123&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin
S Bafna, S Kaur, N Momi and S K Batra
Abstract: http://links.ealert.nature.com/ctt?kn=124&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=115&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
H S Wasan, G M Springett, C Chodkiewicz, R Wong, J Maurel, C Barone, B Rosbrook, A D Ricart, S Kim and J-P Spano
Abstract: http://links.ealert.nature.com/ctt?kn=116&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=117&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
BRCA1 tumours correlate with a HIF-1[alpha] phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression
M Yan, M Rayoo, E A Takano, H Thorne and S B Fox
Abstract: http://links.ealert.nature.com/ctt?kn=118&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=110&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma
N S Vasudev, S Sim, D A Cairns, R E Ferguson, R A Craven, A Stanley, J Cartledge, D Thompson, P J Selby and R E Banks
Abstract: http://links.ealert.nature.com/ctt?kn=111&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=114&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
VEGF121b, a new member of the VEGFxxxb family of VEGF-A splice isoforms, inhibits neovascularisation and tumour growth in vivo
E S Rennel, A H R Varey, A J Churchill, E R Wheatley, L Stewart, S Mather, D O Bates and S J Harper
Abstract: http://links.ealert.nature.com/ctt?kn=64&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=65&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Salivary analysis of oral cancer biomarkers
T Shpitzer, Y Hamzany, G Bahar, R Feinmesser, D Savulescu, I Borovoi, M Gavish and R M Nagler
Abstract: http://links.ealert.nature.com/ctt?kn=61&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=62&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
----------------------
EPIDEMIOLOGY
----------------------
A cohort study of the risk of cancer associated with type 2 diabetes
A A Ogunleye, S A Ogston, A D Morris and J M M Evans
Abstract: http://links.ealert.nature.com/ctt?kn=57&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=58&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Serum triglyceride concentrations and cancer risk in a large cohort study in Austria
H Ulmer, W Borena, K Rapp, J Klenk, A Strasak, G Diem, H Concin and G Nagel VHM & PP Study Group
Abstract: http://links.ealert.nature.com/ctt?kn=55&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=56&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa
B-J Feng, M Khyatti, W Ben-Ayoub, S Dahmoul, M Ayad, F Maachi, W Bedadra, M Abdoun, S Mesli, H Bakkali, M Jalbout, M Hamdi-Cherif, K Boualga, N Bouaouina, L Chouchane, A Benider, F Ben-Ayed, D E Goldgar and M Corbex
Abstract: http://links.ealert.nature.com/ctt?kn=59&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Birth intervals and breast cancer risk
A Kauppila, P Kyyronen, M Hinkula and E Pukkala
Abstract: http://links.ealert.nature.com/ctt?kn=76&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=77&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
----------------------
LETTERS TO THE EDITOR
----------------------
Somatic mutations are present in all members of the AKT family in endometrial carcinoma
A Dutt, H B Salvesen, H Greulich, W R Sellers, R Beroukhim and M Meyerson
http://links.ealert.nature.com/ctt?kn=82&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Reply: Somatic mutations are present in all members of the AKT family in endometrial carcinoma
K Shoji, K Oda, S Nakagawa, S Hosokawa, G Nagae, Y Uehara, K Sone, Y Miyamoto, H Hiraike, O Hiraike-Wada, T Nei, K Kawana, H Kuramoto, H Aburatani, T Yano and Y Taketani
http://links.ealert.nature.com/ctt?kn=69&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
H Rezaei Kalantari
http://links.ealert.nature.com/ctt?kn=71&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer
A A M van der Veldt, E Boven, A J M van den Eertwegh and J B A G Haanen
http://links.ealert.nature.com/ctt?kn=73&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
---------------------------------------------------------------------
Ensure your access to British Journal of Cancer
If you are unable to access the articles in this Table of Contents
e-alert, your library may not subscribe to this journal. Our online
recommendation form is a simple way to make your librarian aware
that this journal is valuable to your research.
Recommend now at
http://links.ealert.nature.com/ctt?kn=32&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted in to receive it.
You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=29&m=34090078&r=MTc2MDAwMTgxNgS2&b=2&j=NTg3MjQyMzkS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne - San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
© Copyright 2009 Nature Publishing Group
=====================================================================
